Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study

Table 1

Baseline data of included studies.

NO Author	Tivantinib group						Control group
	Number	Age	Female (n)	ECOG status 0/1 (n)	AFP >200 ng/mL	Methods	Number	Age	Female (n)	ECOG status 0/1 (n)	AFP >200 ng/mL	Methods
1 Rimassa 2018 [11]	226	66 (19–87), median (range)	27	141/85	97	Tivantinib 120 mg twice daily	114	65 (26–84)	7	66/48	48	Placebo
2 Kobayashi 2017 [20]	134	—	—	—	—	Tivantinib 120 mg twice daily	61	—	—	—	—	Placebo
3 Santoro 2013 [9]	22	71 (47–83), median (range)	2	16/6	11	Tivantinib 240 mg twice daily	15	69 (46–85)	4	6/9	11	Placebo